Dulaglutide for irregular periods in teenage girls with type 1 diabetes
Tests dulaglutide for menstrual irregularities in adolescent girls with type 1 diabetes.
Plain-language title generated from the registry record
Registry title: Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes Mellitus
Key facts
- Where
- Cairo, EgyptSee the site
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 18 years old?
Source: NCT07319286, who can take part
Where in Egypt
- Ain Shams UniversityCairo, EgyptNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ain Shams University
- Trial code
- NCT07319286
- Record updated
- 5 June 2026
- Original description
The aim of this study is to measure the frequency of menstrual irregularities among adolescent females with Type 1 diabetes mellitus and to assess the therapeutic effect of glucagon-like peptide-1 receptor agonist on menstrual irregularities in adolescent females with Type 1 diabetes mellitus .Read full original descriptionShow less
Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes Mellitus
The aim of this study is to measure the frequency of menstrual irregularities among adolescent females with Type 1 diabetes mellitus and to assess the therapeutic effect of glucagon-like peptide-1 receptor agonist on menstrual irregularities in adolescent females with Type 1 diabetes mellitus .
Inclusion: Diagnosis of Type 1 Diabetes Mellitus according to ISPAD criteria; Use of continuous glucose monitoring (CGM); Receiving regular insulin therapy; Regular follow-up at a diabetes clinic; Female participants aged 12 to 18 years; At least 2 years post-menarche; Poor glycemic control, defined as HbA1c ≥ 7%.
Exclusion: Presence of medical conditions known to cause menstrual irregularities, including:(Connective tissue disorders, Autoimmune diseases, Clinical thyroid dysfunction, Neurological diseases); History of severe hypoglycemia within the past 12 months; Other causes of abnormal uterine bleeding, including:(Structural causes (e.g., leiomyoma, endometrial polyp), Coagulation disorders, Ovulatory disorders (e.g., hyperprolactinemia, hyperandrogenism), Iatrogenic causes (e.g., steroid therapy, oral contraceptive use); Family history of medullary thyroid carcinoma or multiple endocrine neoplasia History of pancreatitis.